Vanderbilt Basic Sciences
-
James Crowe awarded “TIME” Best Inventions of 2022
Dr. James Crowe Jr., director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center, led the team that discovered a monoclonal antibody combination that protects against COVID-19. Optimized and developed by AstraZeneca, the monoclonal antibody combination called Evusheld is the first treatment… Read MoreDec. 5, 2022
-
Lindsley named 2022 fellow of American Society for Pharmacology and Experimental Therapeutics
Craig W. Lindsley, University Distinguished Professor of Pharmacology, Biochemistry and Chemistry, who holds the William K. Warren, Jr. Chair in Medicine, was recently announced as a 2022 fellow of the American Society for Pharmacology and Experimental Therapeutics for his demonstrated excellence and… Read MoreNov. 30, 2022
-
Lab-to-Table Conversation: ‘The Impact of Obesity on Health’ Nov. 30
Obesity is a well-known risk factor for diseases such as heart disease, cancer and diabetes. However, it is often considered to be a risk factor brought on by choice, or by inaction. This stigma, in combination with body image norms, oversimplifies obesity as it also complicates how individuals and society… Read MoreNov. 22, 2022
-
Vanderbilt’s Monteggia and Kavalali are awarded the Anna-Monika Prize
Lisa Monteggia, Barlow Family Director of the Vanderbilt Brain Institute and professor of pharmacology, and Ege Kavalali, chair of the Department of Pharmacology and William Stokes Professor of Experimental Therapeutics, have been awarded the first prize by the Anna-Monika Foundation. Read MoreNov. 18, 2022
-
Hawiger still blazing a trail in inflammation research
Fifty-five years after he arrived at Vanderbilt University Medical Center, Jacek Hawiger, MD, PhD, Louise B. McGavock Professor and distinguished professor of Medicine, continues to blaze a trail through the wilderness of inflammation. His group’s latest finding, published Nov. 7 in the journal Scientific Reports, describes a new investigational peptide… Read MoreNov. 18, 2022
-
Vanderbilt, international collaborators discover treatment to slow neurodegenerative diseases
Craig Lindsley, the William K. Warren, Jr. Professor of Medicine and director of Vanderbilt University’s Warren Center for Neuroscience Drug Discovery, and Jeffrey Conn, founding director of the WCNDD and professor emeritus of pharmacology, have contributed seminal work… Read MoreNov. 15, 2022
-
Basic Sciences mourns the loss of Reynolds
By Leah Mann Graduate student Sarah Kurley with thesis advisor Al Reynolds. (Photo by Mary Donaldson) Albert “Al” Reynolds, celebrated and respected professor of pharmacology, emeritus, passed away earlier in November. He had retired in August after 26 years at Vanderbilt University. In the nearly three decades of Reynolds’ affiliation… Read MoreNov. 15, 2022
-
Weight cycling worsens the body’s ability to control glucose levels
By Caroline Cencer Alyssa Hasty The laboratory of Professor of Molecular Physiology and Biophysics Alyssa Hasty recently published a study stressing the importance of glucose homeostasis in maintaining healthy body function. While examining blood glucose levels in diet-induced obese mice, co-first authors Nathan Winn and Matthew Cottam, a… Read MoreNov. 14, 2022
-
Gene mutations impair gut barrier
All of us suffer from gastrointestinal (GI) distress from time to time, but people with mutations in the SLC12A2gene suffer from chronic GI infections, intestinal obstruction, constipation, nutrient malabsorption and blood in the intestine. To understand why this mutation causes such intense GI distress, Eric Delpire, PhD,… Read MoreNov. 10, 2022
-
Alzheimer’s risk factor and cognition
A genetic variant of apolipoprotein E (APOE), a protein involved in fat metabolism, is the strongest common genetic risk factor for Alzheimer’s disease (AD) and contributes to worse cognition in older adults. However, many people who have the variant (APOE-e4) remain cognitively normal as they age, suggesting there may be… Read MoreNov. 10, 2022